Olymvax Announces Successful Phase III Unblinding of Recombinant Staphylococcus Aureus Vaccine with 73.25% Protective Efficacy

A vaccine candidate developed from scratch by a small Chinese biotech and a military medical university has cleared one of the hardest hurdles in clinical research — and by a wider margin than its creators anticipated.

Chengdu Olymvax Biopharmaceuticals Inc. (SSE: 688319) disclosed on July 10 that its recombinant Staphylococcus aureus vaccine, produced using an E. coli expression system, has completed unblinding and primary statistical analysis of its Phase III clinical trial. The results: a protective efficacy of 73.25%, well above the 60% threshold set in the trial protocol. Safety, tolerability, and immunogenicity data were all favorable, the company said.

The news, first reported by People's Financial News, marks a significant milestone for a field that has long struggled to produce a viable vaccine against Staphylococcus aureus — a bacterium responsible for some of the most stubborn and deadly hospital-acquired infections worldwide.

A difficult target

Staphylococcus aureus is among the most formidable pathogens in modern medicine. It causes infections ranging from skin abscesses to life-threatening bloodstream infections, pneumonia, and bone infections. The rise of methicillin-resistant Staphylococcus aureus — MRSA — has made prevention all the more urgent, yet no vaccine has ever reached the market.

Multiple pharmaceutical giants have tried and failed. The bacterium's complex immune evasion mechanisms have derailed more than a dozen clinical programs over the past two decades.

An unlikely partnership

Olymvax, listed on the Shanghai Stock Exchange's STAR Market, co-developed the vaccine with the Army Medical University of the People's Liberation Army. The collaboration pairs a relatively small commercial biotech with one of China's premier military medical research institutions — a combination that reflects both the scientific ambition and the regulatory complexity of the project.

The company described the vaccine as a globally original product, meaning the antigen design and the E. coli-based manufacturing platform were developed independently rather than licensed from overseas partners.

Beating the benchmark

The 73.25% efficacy figure is notable not just because it cleared the regulatory bar, but because it exceeded the protocol's pre-specified target of 60% by more than 13 percentage points. In vaccine development, beating the design target at unblinding is uncommon — and it gives regulators and investors something concrete to look at.

The company also reported that the vaccine demonstrated acceptable safety and tolerability profiles, along with positive immunogenicity data — though it has not yet released the granular details on adverse events or antibody titers.

What happens next will determine whether Olymvax can convert a promising data read into a marketable product — or join the long list of Staphylococcus vaccine programs that looked good in trial but never reached a patient.